Journal of Clinical Oncology
Articles in this Issue
Chemotherapy or targeted therapy?: Real-world comparative outcomes in advanced and recurrent head and neck cancer in resource-limited settings.
e18013 Background: Head and neck cancer (HNC) poses a significant global health burden, with 1.43 million new cases and 0....
Disparities in cancer screening across disease sites for transgender and gender-diverse patients.
10530 Background: Over 2 million Americans identify as transgender, nonbinary, or gender-diverse (TGD) and limited data ex...
Clinical and demographic determinants of overall survival in early-onset head and neck cancers: A multicenter database study.
e18118 Background: The incidence of early-onset (EO) head and neck cancers (HNC), defined as diagnosis before age 50 years...
Clinical predictors and disparities in second primary malignancy risk and survival after index head and neck cancer: A SEER population analysis.
e18090 Background: Survivors of head and neck squamous cell carcinoma (HNSCC) carry a substantial lifelong risk of develop...
Real-world comparison of Dara-VRD, VRD, and Dara-RD in transplant-ineligible older adults with newly diagnosed multiple myeloma.
e19561 Background: Older adults with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible represent a cli...
Representation of classical and rare head and neck cancers in basket clinical trials: A pooled analysis.
e18137 Background: Basket clinical trials (BCTs) aim to expand access to novel therapies across tumor types, including rar...
Effects of RPL37 on the proliferation, migration, and invasion of non–small cell lung cancer cells.
e20513 Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despi...
Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with <i>ERBB2</i> alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.
3104 Background: TAPUR is a phase II basket study evaluating the antitumor activity of commercially available targeted age...
Emergence of single-week adjuvant breast radiation therapy for early-stage breast cancer in the United States.
e12500 Background: Over the past two decades, adjuvant radiation therapy (RT) following lumpectomy for early-stage...
Ultra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment.
5611 Background: For endometrial cancer (EC), clinicopathologic and molecular characterization add to the risk stratificat...
Prostate cancer prevalence in Ohio: Rural–urban differences, environmental toxicity, and correlation with breast cancer incidence.
e22626 Background: Prostate cancer is one of the most common cancers among men worldwide and in the United States. Socioec...
Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States.
e16039 Background: Guidelines endorse testing patients (pts) with advanced (adv) gastric cancer (GC) or gastroesophageal j...
Impact of chronic kidney disease on toxicity patterns and economic burden in CAR T-cell therapy for multiple myeloma: A national analysis.
e19536 Background: Chronic kidney disease (CKD) may impair physiologic resilience during chimeric antigen receptor (CAR) T...
Decomposing the co-mutational landscape of NSCLC by unsupervised learning to unveil components with impact on overall survival.
8041 Background: The molecular characterization of non-small cell lung cancer (NSCLC) and targeting therapies are improvin...
Enhanced pre-biopsy risk stratification for aggressive prostate cancer using prostate density in an EHR-derived cohort.
e17127 Background: Total prostate-specific antigen (PSA) lacks specificity for distinguishing aggressive prostate cancer (...
TroFuse-022/ENGOT-ov84/GOG-3103 part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer.
TPS5636 Background: There is an unmet clinical need for novel therapies for patients with platinum-sensitive recurrent ova...
Knowledge, attitudes, and factors influencing clinical trial participation among breast cancer patients in Brazil: The LACOG 1123 (ASTRAL) study.
e23209 Background: Despite Brazil’s growing participation in clinical cancer research, data on knowledge, attitudes, and f...
Real-world outcome of low-frequency outpatient monitoring for venetoclax initiation in CLL: Single-center experience.
e19026 Background: Venetoclax (Ven) is a potential treatment for CLL/SLL. However, tumor lysis syndrome (TLS) concerns and...
Routine targeted NGS testing to guide treatment decisions in all-stage NSCLC: Public hospital implementation.
e20752 Background: Next-generation sequencing (NGS) is central to the diagnostic work-up in NSCLC by enabling identificati...
National burden and outcomes of CAR-T therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A retrospective analysis of the Nationwide Inpatient Sample.
e19108 Background: Chimeric antigen receptor (CAR) T-cell therapy achieves durable responses in diffuse large B-cell lymph...
A feasibility study of ApricityCarefor early detection and management of immune-related adverse events in cancer patients receiving immune checkpoint therapies.
e13711 Background: Immune-related adverse events (irAEs) is a leading cause of immune checkpoint therapy (ICT) interruptio...
Addressing barriers to FRα-directed therapy integration in platinum-resistant ovarian cancer: A multi-phase, community-informed initiative.
5601 Background: Antibody–drug conjugates (ADCs) targeting folate receptor alpha (FRα) represent an important therapeutic...
Real-world PSA kinetics and depth of response with ARPI-based triplet therapy in metastatic hormone-sensitive prostate cancer: A single-center retrospective cohort analysis.
e17089 Background: Triplet therapy combining an androgen receptor pathway inhibitor (ARPI) with androgen deprivation thera...
TBCRC 050: A phase 1b/2 trial of niraparib and trastuzumab in HER2-positive metastatic breast cancer (MBC): Efficacy and correlative analyses.
1056 Background: Resistance to HER2-directed therapies remains a major challenge in HER2-positiveMBC. In preclinical model...
An actionable machine learning–driven clinicogenomic model as a predictor of brain metastasis risk in breast cancer.
106 Background: Brain metastasis (BM) is a frequent site of disease progression for patients living with metastatic breast...